-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
November 14 is the United Nations Diabetes Day, statistics show that there are more than 500 million diabetics in the world, and China is the country with the largest number of diabetics, with a total of about 125 million
.
.
As an important category of chronic disease drugs, the overall sales scale of diabetes drugs in China's urban physical pharmacy terminals has steadily increased, and is expected to exceed 11.
8 billion yuan in 2022.
8 billion yuan in 2022.
"Yaowang" sold more than 1 billion, Yangtze River, Sino-US East China advanced into the TOP20 brand; 14 exclusive products support 78% of the market for diabetic proprietary Chinese medicine, Baiyunshan ranks in the TOP1, with an amazing rise in Ling, and the new Chinese medicine drugs approved for marketing in 2020 are on the TOP20 list
.
China's urban physical pharmacy terminal diabetes medication is blooming, and the potential is promising
.
.
China's urban physical pharmacy terminal diabetes medication is blooming, and the potential is promising
.
Figure 1: Total sales of terminal diabetes drugs in physical pharmacies in Chinese cities (10,000 yuan)
According to data from Minai.
com, in 2022, it is expected that in China's urban physical pharmacy terminals, the sales scale of diabetes drugs and chemical drugs (including biological drugs) will increase by 12.
1% to 11.
48 billion yuan, the highest value
in nearly eight years.
In terms of proprietary Chinese medicines, the sales scale of diabetes drugs in the past three years has remained at the level of 390 million yuan, and it is expected to decrease slightly by 1.
23%
in 2022.
Overall, the market size of diabetes drugs (chemical drugs, biological drugs, and proprietary Chinese medicines) is expected to be more than 11.
8 billion yuan in 2022, with a total sales growth rate of 11.
6%.
com, in 2022, it is expected that in China's urban physical pharmacy terminals, the sales scale of diabetes drugs and chemical drugs (including biological drugs) will increase by 12.
1% to 11.
48 billion yuan, the highest value
in nearly eight years.
In terms of proprietary Chinese medicines, the sales scale of diabetes drugs in the past three years has remained at the level of 390 million yuan, and it is expected to decrease slightly by 1.
23%
in 2022.
Overall, the market size of diabetes drugs (chemical drugs, biological drugs, and proprietary Chinese medicines) is expected to be more than 11.
8 billion yuan in 2022, with a total sales growth rate of 11.
6%.
01, the hypoglycemic "medicine king" sold 1 billion! Gan and Li, Yangtze River, and East China broke the dominance of foreign brands
Insulin and its analogues remain the most popular subcategory, with sales expected to exceed 3.
6 billion yuan in 2022, with a growth rate of 3.
3%.
Biguanide is expected to have sales of more than 1.
9 billion yuan, with a growth rate of 1.
42%.
After an increase of 81.
09% in GLP-1 receptor agonists last year, it is expected to grow as high as 148.
26% this year, exceeding 1 billion yuan
for the first time.
These three sub-categories with sales of more than 1 billion yuan are expected to have a combined market share of more than 57%
in 2022.
6 billion yuan in 2022, with a growth rate of 3.
3%.
Biguanide is expected to have sales of more than 1.
9 billion yuan, with a growth rate of 1.
42%.
After an increase of 81.
09% in GLP-1 receptor agonists last year, it is expected to grow as high as 148.
26% this year, exceeding 1 billion yuan
for the first time.
These three sub-categories with sales of more than 1 billion yuan are expected to have a combined market share of more than 57%
in 2022.
Table 1: 2022E Top 20 products of terminal diabetes drugs, chemicals (including biological drugs) in Chinese urban physical pharmacies
In 2022, it is expected that the total sales of TOP20 products will exceed 8.
8 billion yuan, with a total share of 77%, and the market concentration is high
.
The ratio of oral to injection was 11:9, the injection was no longer insulin and its analogues, and 3 GLP-1 receptor agonists successfully broke through
.
8 billion yuan, with a total share of 77%, and the market concentration is high
.
The ratio of oral to injection was 11:9, the injection was no longer insulin and its analogues, and 3 GLP-1 receptor agonists successfully broke through
.
Figure 2: Sales of metformin hydrochloride tablets (billion)
Metformin is a biguanide diabetes treatment drug, clinically mainly used in obese diabetes patients, its hypoglycemic effect is stable and not easy to appear hypoglycemia, but also can reduce weight, reduce blood lipids, has a certain cardiovascular protective effect, the latest domestic and foreign guidelines will position metformin as a first-line treatment, and can be combined with most oral hypoglycemic drugs and insulin
.
.
At the terminal of physical pharmacies in China's cities, the sales of metformin hydrochloride tablets have maintained a positive growth trend, defeating acarbose tablets in 2020 to become the top 1 product for diabetes medicine, with sales exceeding 1 billion yuan for the first time in 2021 and expected sales to rise to 1.
058 billion yuan
in 2022.
Metformin hydrochloride tablets are the only chemical products
with more than 1 billion yuan for diabetes medication.
058 billion yuan
in 2022.
Metformin hydrochloride tablets are the only chemical products
with more than 1 billion yuan for diabetes medication.
Figure 3: Sales of three GLP-1 receptor agonists in recent years (RMB 100 million)
GLP-1 receptor agonists can stimulate the natural secretion of insulin, but also inhibit the secretion of glucagon and protect islet B cells, reduce caloric intake by suppressing appetite, reduce blood sugar levels, and have a certain weight loss effect
.
.
Semeglutide injection and dulaglutide injection are the new products
on this year's TOP20 list.
Dula glycopeptide injection was approved to enter the domestic market in 2019, and has maintained a triple-digit growth rate every year, and the terminal sales of physical pharmacies in Chinese cities are expected to be 195 million yuan
in 2022.
Semeglutide injection was approved to enter the domestic market in 2021, and the expected sales growth rate in 2022 is 550.
60%, with sales as high as 573 million yuan, the product only needs to be injected subcutaneously once a week, which has weight loss and cardiovascular protection effects while reducing glucose, although the market time is short but extremely popular, and the market potential can be expected
.
on this year's TOP20 list.
Dula glycopeptide injection was approved to enter the domestic market in 2019, and has maintained a triple-digit growth rate every year, and the terminal sales of physical pharmacies in Chinese cities are expected to be 195 million yuan
in 2022.
Semeglutide injection was approved to enter the domestic market in 2021, and the expected sales growth rate in 2022 is 550.
60%, with sales as high as 573 million yuan, the product only needs to be injected subcutaneously once a week, which has weight loss and cardiovascular protection effects while reducing glucose, although the market time is short but extremely popular, and the market potential can be expected
.
Table 2: 2022E Top 20 brands of diabetes drugs, chemical drugs (including biological drugs) in China's urban physical pharmacies
In 2022, it is expected that the total sales of TOP20 brands will exceed 7.
3 billion yuan, with a total share of nearly 64%, and the market concentration is still high
.
The ratio of foreign brands to domestic brands is 17:3, with Novo Nordisk's semeglutide injection, Eli Lilly's dulaglutide injection and Boehringer Ingelheim's lintagliptin tablets being new brands this year, while Gan&Lee Pharmaceutical's insulin glargine injection, Yangtze River Nanjing Hailing Pharmaceutical's epastistat tablets and Hangzhou Sino-American Huadong Pharmaceutical's acarbose tablets grabbed three seats
in the fierce competition.
3 billion yuan, with a total share of nearly 64%, and the market concentration is still high
.
The ratio of foreign brands to domestic brands is 17:3, with Novo Nordisk's semeglutide injection, Eli Lilly's dulaglutide injection and Boehringer Ingelheim's lintagliptin tablets being new brands this year, while Gan&Lee Pharmaceutical's insulin glargine injection, Yangtze River Nanjing Hailing Pharmaceutical's epastistat tablets and Hangzhou Sino-American Huadong Pharmaceutical's acarbose tablets grabbed three seats
in the fierce competition.
Figure 4: Sales of eppasti tablets of Yangtze River Nanjing Hailing Pharmaceutical (100 million yuan)
The indications of epastim tablets are diabetic neuropathy, in recent years, with the awakening of patients' consciousness, early detection and early treatment of diabetic neuropathy can effectively avoid serious complications, and the sales of this class of drugs have grown rapidly
.
At present, only 4 domestic pharmaceutical companies have obtained production approvals for epalstat tablets, and Yangzijiang Nanjing Hailing Pharmaceutical is the leading enterprise
.
At the terminal of physical pharmacies in China's cities, epalstat tablets of Yangtze River Nanjing Hailing Pharmaceutical have maintained a double-digit growth rate, exceeding 100 million yuan in 2020 and expected sales of more than
200 million yuan in 2022.
In terms of market ranking, the brand squeezed into the TOP17 in 2020 and is expected to rank in the TOP13
in 2022.
.
At present, only 4 domestic pharmaceutical companies have obtained production approvals for epalstat tablets, and Yangzijiang Nanjing Hailing Pharmaceutical is the leading enterprise
.
At the terminal of physical pharmacies in China's cities, epalstat tablets of Yangtze River Nanjing Hailing Pharmaceutical have maintained a double-digit growth rate, exceeding 100 million yuan in 2020 and expected sales of more than
200 million yuan in 2022.
In terms of market ranking, the brand squeezed into the TOP17 in 2020 and is expected to rank in the TOP13
in 2022.
02, Baiyun Mountain, Yiling.
.
.
14 exclusive proprietary Chinese medicine screens, new Chinese medicine drugs soared 232%
.
.
14 exclusive proprietary Chinese medicine screens, new Chinese medicine drugs soared 232%
The market size of proprietary Chinese medicines for terminal diabetes in China's urban physical pharmacies has remained at about 400 million yuan, peaking at 446 million yuan in 2018 and expected to be 393 million yuan
in 2022.
in 2022.
Table 3: 2022E Top 20 proprietary Chinese medicine products for terminal diabetes in China's urban physical pharmacies
Note: Sales of less than 10 million yuan are replaced with *
In 2022, the total sales of TOP20 products will be 369 million yuan, with a total share of 94%, of which the total share of 14 exclusive products exceeds 78%, and the market concentration is quite high
.
.
Thirst Quenching Pill is an exclusive product of Baiyun Mountain Zhongyi Pharmaceutical, which is used to treat polydipsia, polyuria, polyphagia, weight loss, fatigue and weakness, poor sleepiness, low back pain, urine sugar and elevated blood sugar
.
From 2015 to 2022, E has always ranked in the top 1 product in the terminal diabetes drug proprietary Chinese medicine market of China's urban physical pharmacies, and it is also the only product with sales of 100 million yuan, and the sales are expected to be more than
120 million yuan in 2022.
.
From 2015 to 2022, E has always ranked in the top 1 product in the terminal diabetes drug proprietary Chinese medicine market of China's urban physical pharmacies, and it is also the only product with sales of 100 million yuan, and the sales are expected to be more than
120 million yuan in 2022.
Figure 5: Sales of Jinlida granules (million yuan)
Jinlida granules are the exclusive products of Shijiazhuang Yiling Pharmaceutical, which is used to treat type 2 diabetes mellitus
.
The sales of the product in China's urban physical pharmacy terminals have grown rapidly in the past three years, exceeding 10 million yuan in 2021 and expected to exceed 36 million yuan in 2022, and the market ranking has jumped to TOP3
.
.
The sales of the product in China's urban physical pharmacy terminals have grown rapidly in the past three years, exceeding 10 million yuan in 2021 and expected to exceed 36 million yuan in 2022, and the market ranking has jumped to TOP3
.
Figure 6: Registration status of mulberry total alkaloid tablets
Sangzhi Total Alkaloids is a Class 5 new Chinese medicine approved for marketing in 2020 for the treatment of type 2 diabetes
.
The product will grow by four digits in China's urban physical pharmacy terminal in 2021, and is expected to grow by 232% in 2022, with sales at the level
of 7 million yuan.
.
The product will grow by four digits in China's urban physical pharmacy terminal in 2021, and is expected to grow by 232% in 2022, with sales at the level
of 7 million yuan.
Table 4: 2022E Top 20 brands of proprietary Chinese medicines for terminal diabetes in Chinese urban physical pharmacies
Note: Sales of less than 1 million yuan are replaced with *
In 2022, the total sales of TOP20 brands will exceed 350 million yuan, with a total share of 90%, and the market concentration is very high
.
7 non-exclusive brands were on the list, Shanxi Guangyu Yuanguo Medicine's manna thirst quenching capsules were new brands, and Henan Lingrui Pharmaceutical's ginseng stilbene hypoglycemic capsules also increased by
51%.
.
7 non-exclusive brands were on the list, Shanxi Guangyu Yuanguo Medicine's manna thirst quenching capsules were new brands, and Henan Lingrui Pharmaceutical's ginseng stilbene hypoglycemic capsules also increased by
51%.
Figure 7: Sales of ginseng hypoglycemic capsules of Henan Lingrui Pharmaceutical (10,000 yuan)
Ginseng Hypoglycemic Capsules are used to treat thirst and treat type 2 diabetes
.
At present, there are two enterprises that have obtained the approval of this product, Henan Lingrui Pharmaceutical leads the market, the brand increased by more than 80% in 2021, sales exceeded 10 million yuan, and is expected to increase by 51% in 2022, reaching more than
26 million yuan.
.
At present, there are two enterprises that have obtained the approval of this product, Henan Lingrui Pharmaceutical leads the market, the brand increased by more than 80% in 2021, sales exceeded 10 million yuan, and is expected to increase by 51% in 2022, reaching more than
26 million yuan.
Source: Minainet database
Note: Minai.
com's "Competition Pattern of Drug Terminal in China's Urban Physical Pharmacies", the statistical scope is: physical pharmacies in cities at the prefecture level and above nationwide, excluding county and rural pharmacies; The above sales are calculated
based on the average retail price of the product at the terminal.
com's "Competition Pattern of Drug Terminal in China's Urban Physical Pharmacies", the statistical scope is: physical pharmacies in cities at the prefecture level and above nationwide, excluding county and rural pharmacies; The above sales are calculated
based on the average retail price of the product at the terminal.
